Healthcare Conference Schedules and Additional Loans - Research Report on Clovis Oncology, LifePoint, Halozyme, Infinity, and

  Healthcare Conference Schedules and Additional Loans - Research Report on
        Clovis Oncology, LifePoint, Halozyme, Infinity, and Endologix

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, January 9, 2014

NEW YORK, January 9, 2014 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Clovis
Oncology, Inc. (NASDAQ: CLVS), LifePoint Hospitals, Inc. (NASDAQ: LPNT),
Halozyme Therapeutics, Inc. (NASDAQ: HALO), Infinity Pharmaceuticals, Inc.
(NASDAQ: INFI), and Endologix, Inc. (NASDAQ: ELGX). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Clovis Oncology, Inc. Research Report

On January 6, 2014, Clovis Oncology, Inc. (Clovis Oncology) announced that it
will present at the 32^nd Annual J.P. Morgan Healthcare Conference on January
13, 2014. The Company stated that CEO and President, Patrick J. Mahaffy, is
scheduled to present at 3:30 p.m. PT at the conference, which will be held at
the Westin St. Francis Hotel in San Francisco. Clovis Oncology added that live
webcast of the presentation can be accessed through the Investor Relations
section of its website, where a replay of the webcast will be available for 30
days. The Full Research Report on Clovis Oncology, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/6a2a_CLVS

--

LifePoint Hospitals, Inc. Research Report

On January 6, 2014, LifePoint Hospitals, Inc. (LifePoint) announced that
management team of the Company will participate in the 32^nd Annual J.P.
Morgan Healthcare Conference, which will take place from January 13, 2014 to
January 16, 2014 in San Francisco. The Company stated that a live broadcast of
the presentation can be accessed at its website on January 13, 2014 at 11:00
a.m. PT. LifePoint added that a replay of the broadcast will also be available
for 30 days on the Company's website. The Full Research Report on LifePoint
Hospitals, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/f06d_LPNT

--

Halozyme Therapeutics, Inc. Research Report

On January 6, 2014, Halozyme Therapeutics, Inc. (Halozyme) announced that it
has secured an additional $20 million loan from Oxford Finance and Silicon
Valley Bank. The Company informed that on December 27, 2013, it entered into
an Amended and Restated Loan and Security Agreement that extends the original
$30 million term loan and provides for an additional $20 million term loan,
bringing the total loan balance to $50 million. Halozyme added that maturity
date of the term loan is January 1, 2018. The Company stated that the proceeds
of the loan will be utilized for working capital and other near-term growth
initiatives. The Full Research Report on Halozyme Therapeutics, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/ea1b_HALO

--

Infinity Pharmaceuticals, Inc. Research Report

On January 6, 2014, Infinity Pharmaceuticals, Inc. (Infinity) announced its
participation at the J.P. Morgan 32^nd Annual Healthcare Conference in San
Francisco, California. The Company stated that its presentation is scheduled
at 10:00 a.m. PT / 1:00 p.m. ET on January 13, 2014. Infinity added that a
live webcast of the presentation can be accessed via the investors/media
section of its website, and will be available for 30 days after the event. The
Full Research Report on Infinity Pharmaceuticals, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/3862_INFI

--

Endologix, Inc. Research Report

On January 6, 2014, Endologix, Inc. (Endologix) announced its participation at
the 32^nd Annual J.P. Morgan Healthcare Conference in San Francisco,
California. The Company stated that President and CEO, John McDermott, is
scheduled to present on January 13, 2014 at 9:00 a.m. PT / 12:00 p.m. ET.
Endologix added that an audio webcast of the presentation will be available
under the investor relations section of its website, where a replay will also
be available for 30 days. The Full Research Report on Endologix, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/2f8d_ELGX

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE AAA Research Reports

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.